Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.67 |
| ▸ | CTSL | P07711 | 9/20 | 0.62 |
| ▸ | CTSB | P07858 | 8/20 | 0.62 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14491127 | 0.90 | CTSS (0.69) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL5181737 | 0.90 | CTSS (0.69) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL29946200 | 0.90 | CTSS (0.69) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL6449419 | 0.82 | CTSB (0.67) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL7031248 | 0.81 | CTSL (0.77) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL7031241 | 0.81 | CTSL (0.77) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL7026935 | 0.81 | CTSL (0.77) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL7411039 | 0.80 | CTSS (0.69) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL7411037 | 0.80 | CTSS (0.69) | CTSSCTSLCTSBCTSKCTSH | |
| SCHEMBL7411052 | 0.80 | CTSS (0.69) | CTSSCTSLCTSBCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | claimed |
| WO-2013036766-A1 | SMALL MOLECULE NAPHTHOQUINONE- AND PHTHALIMIDE-BASED LIPOCATIONS AS ANTI-PARASITIC AGENTS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2005107470-A2 | USE OF CARBONIC ANHYDRASE INHIBITORS FOR INSECT CONTROL AND MALARIA TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | CAT, CTSA, CTRL | CTSS 5/4885CTSL 26/4885CTSB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.